Suppr超能文献

肝脏X受体通路的激活抑制原代人肝细胞中的乙肝病毒复制。

Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes.

作者信息

Zeng Jing, Wu Daitze, Hu Hui, Young John A T, Yan Zhipeng, Gao Lu

机构信息

Roche Innovation Center Shanghai, Shanghai, China.

Roche Innovation Center Basel, Basel, Switzerland.

出版信息

Hepatology. 2020 Dec;72(6):1935-1948. doi: 10.1002/hep.31217.

Abstract

BACKGROUND AND AIMS

Hepatitis B virus (HBV) infection is ranked among the top health priorities worldwide. Accumulating evidence suggests that HBV infection and replication are closely associated with liver metabolism. The liver X receptors (LXRs), which belong to the superfamily of nuclear hormone receptors, are important physiological regulators of lipid and cholesterol metabolism. However, the association between the LXR pathway and HBV infection remains largely unclear.

APPROACH AND RESULTS

In this study, the antiviral activity of LXR agonists was investigated using multiple HBV cellular models. We observed that in HBV-infected primary human hepatocytes (PHHs), synthetic LXR agonists (T0901317, GW3965, and LXR-623), but not an LXR antagonist (SR9238), potently inhibited HBV replication and gene expression, as demonstrated by substantial reductions in viral RNA, DNA, and antigen production following agonist treatment. However, covalently closed circular DNA (cccDNA) levels were not significantly reduced by the agonists. In addition, no rebound in viral replication was observed after treatment withdrawal, indicating a long-lasting inhibitory effect. These results suggest that LXR agonists decrease the transcriptional activity of cccDNA. In contrast, no significant anti-HBV effect was observed in HepG2-derived cell lines. Interestingly, LXR agonist treatment strongly reduced cholesterol 7α-hydroxylase 1 (CYP7A1) mRNA levels. Knockdown of CYP7A1 gene expression with small interfering RNA inhibited HBV activity in PHHs, suggesting CYP7A1 as a potential factor contributing to the antiviral effects of LXR agonists.

CONCLUSIONS

We found that activation of the LXR pathway with synthetic LXR agonists could elicit potent anti-HBV activity in PHHs, possibly through sustained suppression of cccDNA transcription. Our work highlights the therapeutic potential of targeting the LXR pathway for the treatment of chronic HBV infection.

摘要

背景与目的

乙型肝炎病毒(HBV)感染是全球首要的健康问题之一。越来越多的证据表明,HBV感染与复制和肝脏代谢密切相关。肝脏X受体(LXRs)属于核激素受体超家族,是脂质和胆固醇代谢的重要生理调节因子。然而,LXR信号通路与HBV感染之间的关联仍不清楚。

方法与结果

本研究使用多种HBV细胞模型研究了LXR激动剂的抗病毒活性。我们观察到,在HBV感染的原代人肝细胞(PHHs)中,合成LXR激动剂(T0901317, GW3965和LXR-623),而非LXR拮抗剂(SR9238),能有效抑制HBV复制和基因表达,激动剂处理后病毒RNA、DNA和抗原产量显著降低。然而,共价闭合环状DNA(cccDNA)水平并未被激动剂显著降低。此外,停药后未观察到病毒复制反弹,表明有持久的抑制作用。这些结果表明LXR激动剂降低了cccDNA的转录活性。相比之下,在HepG2衍生细胞系中未观察到显著的抗HBV作用。有趣的是,LXR激动剂处理显著降低了胆固醇7α-羟化酶1(CYP7A1)的mRNA水平。用小干扰RNA敲低CYP7A1基因表达可抑制PHHs中的HBV活性,提示CYP7A1是LXR激动剂抗病毒作用的潜在因素。

结论

我们发现,用合成LXR激动剂激活LXR信号通路可在PHHs中引发有效的抗HBV活性,可能是通过持续抑制cccDNA转录。我们的研究突出了靶向LXR信号通路治疗慢性HBV感染的治疗潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验